Things are worsening for UnitedHealth Group (NYSE: UNH), with a significant drop in stock value—losing half its worth in 2025—amid poor financial results, a CEO change, and a Department of Justice investigation. Following a disappointing earnings report, the stock’s future remains uncertain, prompting questions about whether it is best to avoid or consider as a contrarian investment.
Want More Context? 🔎
DuPont (DD) Q2 EPS Jumps 15% on Growth
DuPont de Nemours (NYSE:DD) reported Q2 2025 earnings on August 5, achieving adjusted EPS of $1.12, exceeding expectations, and GAAP revenue of $3,257 million, slightly above consensus. The company experienced significant growth in its electronics and healthcare segments, prompting management to raise full-year guidance despite a GAAP goodwill impairment in its Aramids business. Want More Context? 🔎
Read more